$59.63
2.28% today
Nasdaq, Dec 30, 09:48 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Target price 2024 - Analyst rating & recommendation

TransMedics Group, Inc. Classifications & Recommendation:

Buy
67%
Hold
33%

TransMedics Group, Inc. Price Target

Target Price $102.00
Price $59.28
Potential
Number of Estimates 7
7 Analysts have issued a price target TransMedics Group, Inc. 2025 . The average TransMedics Group, Inc. target price is $102.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 6 Analysts recommend TransMedics Group, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the TransMedics Group, Inc. stock has an average upside potential 2025 of . Most analysts recommend the TransMedics Group, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 241.62 429.50
158.53% 77.76%
EBITDA Margin 3.63% 17.43%
112.44% 380.76%
Net Margin -10.69% 7.37%
75.79% 168.91%

9 Analysts have issued a sales forecast TransMedics Group, Inc. 2024 . The average TransMedics Group, Inc. sales estimate is

$429m
Unlock
. This is
7.08% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$431m 7.53%
Unlock
, the lowest is
$425m 5.94%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $242m 158.53%
2024
$429m 77.76%
Unlock
2025
$523m 21.88%
Unlock
2026
$635m 21.33%
Unlock
2027
$823m 29.54%
Unlock
2028
$949m 15.30%
Unlock

6 Analysts have issued an TransMedics Group, Inc. EBITDA forecast 2024. The average TransMedics Group, Inc. EBITDA estimate is

$74.8m
Unlock
. This is
51.70% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$86.2m 74.65%
Unlock
, the lowest is
$52.5m 6.47%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $8.8m 132.16%
2024
$74.8m 754.42%
Unlock
2025
$105m 39.80%
Unlock
2026
$144m 37.45%
Unlock
2027
$223m 55.16%
Unlock
2028
$279m 25.14%
Unlock

EBITDA Margin

2023 3.63% 112.44%
2024
17.43% 380.76%
Unlock
2025
19.99% 14.69%
Unlock
2026
22.65% 13.31%
Unlock
2027
27.12% 19.74%
Unlock
2028
29.44% 8.55%
Unlock

6 TransMedics Group, Inc. Analysts have issued a net profit forecast 2024. The average TransMedics Group, Inc. net profit estimate is

$31.7m
Unlock
. This is
1.44% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$33.9m 8.62%
Unlock
, the lowest is
$27.9m 10.77%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-25.8m 37.40%
2024
$31.7m 222.52%
Unlock
2025
$47.2m 49.12%
Unlock
2026
$76.6m 62.21%
Unlock
2027
$98.7m 28.85%
Unlock
2028
$119m 20.40%
Unlock

Net Margin

2023 -10.69% 75.79%
2024
7.37% 168.91%
Unlock
2025
9.02% 22.39%
Unlock
2026
12.06% 33.70%
Unlock
2027
11.99% 0.58%
Unlock
2028
12.52% 4.42%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.77 0.94
37.40% 222.08%
P/E 64.69
EV/Sales 5.21

6 Analysts have issued a TransMedics Group, Inc. forecast for earnings per share. The average TransMedics Group, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.94
Unlock
. This is
1.08% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$1.01 8.60%
Unlock
, the lowest is
$0.83 10.75%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.77 37.40%
2024
$0.94 222.08%
Unlock
2025
$1.41 50.00%
Unlock
2026
$2.28 61.70%
Unlock
2027
$2.94 28.95%
Unlock
2028
$3.54 20.41%
Unlock

P/E ratio

Current 65.37 191.66%
2024
64.69 1.04%
Unlock
2025
43.38 32.94%
Unlock
2026
26.74 38.36%
Unlock
2027
20.76 22.36%
Unlock
2028
17.24 16.96%
Unlock

Based on analysts' sales estimates for 2024, the TransMedics Group, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.57 59.75%
2024
5.21 6.54%
Unlock
2025
4.27 17.95%
Unlock
2026
3.52 17.58%
Unlock
2027
2.72 22.81%
Unlock
2028
2.36 13.27%
Unlock

P/S ratio

Current 5.11 61.83%
2024
4.77 6.61%
Unlock
2025
3.91 17.95%
Unlock
2026
3.22 17.58%
Unlock
2027
2.49 22.81%
Unlock
2028
2.16 13.27%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today